Abbreviated Name

Lung Ref Set A App: Massion (2017)

Lead Investigator

Grogan, Eric — Vanderbilt -Ingram Cancer Center

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Grogan, Eric — Vanderbilt -Ingram Cancer Center
• Srivastava, Sudhir — National Cancer Institute
• Zheng, Yingye — Fred Hutchinson Cancer Center

Abstract

No abstract availalbe.

Aims

No aims available.

Analytic Method

No analytic method available.

Comments

No comments available.

Outcome

The CBSI measurement of CYFRA 21-1 is not observed to have discriminatory ability between lung cancer cases and high-risk controls in the dataset sampled from the EDRN Lung Reference Set A. Pre-specied analyses: -sensitivity at 80% specicity: 0:27 (95% CI 0:18; 0:37) - specicity at 80% sensitivity: 0:25 (95% CI 0:16; 0:4). Both observed values are only somewhat greater than 20% (the expected value assuming no discrimination) and 95% condence intervals do not exclude the null. The corresponding positive and negative diagnostic likelihood ratios and the overall AUC similarly do not suggest much discrimination.

Secure Outcome

No secure outcome available.

Publications

• No publications available at this time for this protocol.

Biomarkers

• CYFRA 21-1

Data Collections

• No data collections available at this time for this protocol.

 Team Project

Start Date

Jun 13 2017

Estimated Finish Date

Oct 13 2017

Finish Date

Jan 2 2018

Protocol ID

422

Protocol Type

Reference Set

Fields of Research

• UNKNOWN

Collaborative Group

Lung and Upper Aerodigestive Cancers Research Group

Cancer Types

• Malignant neoplasm of bronchus and lung

Phased Status

1